Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.IVVD · Entity 721 | Director | May 21, 2024 | May 23, 2024 |
| NovaBridge BiosciencesNBP · Entity 6324 | Director · Chief Executive Officer | July 06, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date May 21, 2024 · Filed May 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2034-05-20 | Direct | 100,000 |
Reported balance
After 2024-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-21 · Grant · Acquired 100,000 · Balance 100,000 F1: This option was granted on May 21, 2024 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 21, 2024 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.
NovaBridge Biosciences
Report date July 06, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2025 Employee Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-07-06 | Direct | 3,000,000 |
Reported balance
After 2026-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-06 · Grant · Acquired 3,000,000 · Balance 3,000,000 F1: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F2: The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of July 1, 2026. F3: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").
F2: The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of July 1, 2026.
F3: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 8, 2026 20:26 UTC | NovaBridge Biosciences NBP · Entity 6324 | Grant2025 Employee Share Option (right to buy) · Derivative | 3,000,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0002024011-26-000006 · form4-07082026_080720.xml · derivative · entry 1 Gupta Srishti · CIK 0002024011 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Ordinary Shares · 3,000,000 shares Expires 2036-07-06 F1 · derivative.exercise_price: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F1 · shares: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F2 · derivative.exercise_date: The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of July 1, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F1 · derivative.underlying_shares: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F1 · balance_after: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:56 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0000950170-24-064007 · ownership.xml · derivative · entry 1 Gupta Srishti · CIK 0002024011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2024 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.